

MO HEALTHNET DRUG UTILIZATION REVIEW BOARD

July 19, 2017

Department of Natural Resources, La Charrette/Nightengale Conference Rm, Jefferson City MO

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, Pharm D – Board Chair
Randy Beckner, Pharm D
Sandra Bollinger, Pharm D
Jennifer Passanise, FNP
Stacy Mangum, Pharm D
Ginger Nicol, MD
Glenn Talboy, MD

MHD STAFF PRESENT

Stephen Calloway, RPh, Director of Pharmacy
Angela Wilson, Manager, Band I
Mark Roaseau, RPh, Clinical Pharmacist
Dr. Timothy Kling, MD, Assistant Medical Director
Frances (Franki) Moseley, Administrative Office Support Assistant
Elizabeth Short, Medicaid Specialist
Lisa Smith, Program Development Specialist

DUR BOARD MEMBERS ABSENT

Charlene Heyde, RPh
Kenneth Haller, MD
Kirk Nelson, MD

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Richard Pope, Pharm D, Magellan

OTHERS IN ATTENDANCE

Angie Martin, Abbvie
Victoria Jasion, Abbvie
Evan Rushing, Alkermes
Steve Strong, AstraZeneca
Jodi Jensen, Biogen
Rob Kilo, Biogen
Megan Barton, Home State/Centene
Brent DePriest, GlaxoSmithKline

Jennifer Stoffel, Janssen
Steve Naert, Lilly
Brian Rose, Merck
Melody Webb, MHD
Faith Andrulot, MissouriCare
Jim Bauman, Pfizer
Tucker Borel, Pfizer
Phillip King, Pfizer

Anne McNamara, Otonomy
Terry McCurren, Otsuka
Cheryl Donahue, Sarepta
Chris Stanfield, Spernus
Anthony Locke, Tris Pharma
Heather Maruska, United Healthcare
Casey Johnson, VIIV
Shefali Patel, Wipro

Welcome, Introductions and Opening Remarks	Susan Abdel-Rahman, Pharm D, called the meeting to order. Stephen Calloway, RPh facilitated the meeting on behalf of the MO HealthNet Division (MHD).
Minutes Review and Approval	Minutes of the April 2017 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
Pharmacy Program/Budget Update	Stephen Calloway presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
Review of Prior Authorization Meeting	Copies of the agenda and draft minutes from the June 2017 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
Old Business Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2017 PDL decisions to be implemented July 2017. Pending ratification, PDL decisions from the June 2017 Drug PA Committee meeting will be implemented October 2017. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Drug Review	Stephen Calloway reviewed the new drug products that were identified for the quarter January, February and March 2017, the recommended status within the clinical program. <ul style="list-style-type: none"> • Discussion - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions. • Decision - The listing and recommendations were approved as part of a block vote by the DUR Board (See Roll Call Votes).
Clinical Edits	
Exondys 51	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Spinraza	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Short-Acting (Single-agent) Opioids	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)

Preferred Drug List (PDL) Annual Review	
Amylin Analogs	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Antihyperuricemic Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Bile Salt Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Bone Deossification Suppression Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
BPH Agents (formerly Androgen Hormone Inhibitors)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
Cephalosporin Antibiotics-Oral (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Agents for Cryopyrin-Associated Periodic Syndrome (CAPS)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
DPP-IV Inhibitors	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Electrolyte Depleters	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
FluoroQuinolones	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Gastrointestinal (GI) Antibiotics-Oral (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

GLP-1 Receptor Agonists	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Growth Hormones and Growth Factors	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Hematopoietic Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins-Long Acting	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins-Mix	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Insulins-Rapid Acting	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. Mr. Calloway indicated that MHD was changing its recommendation since the Drug PA Meeting to keep Humalog 200 u / mL KwickPen as “preferred”. ● Decision – This edit was accepted with the updated recommendation and added to the block vote. MHD staff will amend this recommendation at the September Drug PA Committee Meeting. (See Roll Call Votes).
Intravaginal Antibiotics	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Macrolides-Adult	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Macrolides-Pediatric	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Methotrexate-Oral and Injectable (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Multiple Sclerosis Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral AntiDiabetics: Biguanides	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
AntiDiabetic Combinations: Oral and Injectable	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral AntiDiabetics: Meglitinides	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral AntiDiabetics: 2nd Generation Sulfonylureas	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Oral AntiDiabetics: Thiazolidinediones	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Penicillins (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Targeted Immune Modulators (formerly Biologics-DMARDs)	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. A tentative decision had been made at the Drug PA Committee Meeting to grant Cosentyx “preferred” status. However, after clarification of the contract terms, the MHD staff is recommending non-preferred status for Cosentyx. The MHD staff will notify the Drug PA Committee at the September meeting. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Tetracyclines	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Urinary Tract Antispasmodics	<ul style="list-style-type: none"> ● Discussion – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Preferred Drug List Announcement	A handout of therapeutic categories scheduled for Annual Review on September 21, 2017, and renewal on the Preferred Drug List was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page. http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf
Conduent Update	Dr. Luke Boemer presented PMPM Spend and Claims information for the Hepatitis C Agents. Dr. Boehmer presented Hepatitis C and the Calendar Year 2015 and 2016 Viral Load Lab data and the percentage of patients that were compliant with getting their labs drawn at the appropriate time according to AASLD guidelines. Dr. Boemer also presented Hepatitis C data for the number of regimens approved for participants and which therapies resulted in multiple regimens.
Top 25 Drugs by Cost	Dr. Luke Boehmer reviewed the Top 25 Drugs Summary Reports for the 3 rd quarter 2016 through the 2 nd quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Call Center Statistics Clinical Edit Summary Report	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were also provided. Dr. Luke Boehmer presented updated Call Center Statistics for the Short Acting Single Agent Opioids and Short Acting Combination Opioids. Dr. Boehmer also presented utilization data documenting the impact of the edit changes on morphine equivalents and units dispensed.
Drug Utilization Review Activities	Dr. Katie Wilbers presented to the board that the Naloxone mailing went out in June and that the next DUR mailing Psychotropics in Kids, is scheduled for September. Dr. Wilbers reviewed the outcomes from our March 2017 mailing on Medication Adherence which were positive and proposed the next mailing be on Benzodiazepines. Dr. Wilbers also reviewed the proposal, letter and patient insert they would mail out. Dr. Wilbers had a few edits to make at the request of the board which she will bring back to the next meeting.

Adjourn	Sandra Bollinger, Pharm D, made a motion to move to close the meeting under Section 610.021 (5)(14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information .(See attached roll call vote). There were no therapy cases to be presented, so there was no Executive Session. There being no further business, actions or motions the meeting was adjourned. (See attached roll call vote). The next DUR Board meeting is scheduled for October 18, 2017 at the Department of Natural Resources, La Charrette/Nightingale Rooms, 1101 Riverside Dr., Jefferson City, MO.
----------------	---

Roll Call Votes – July 19, 2017

MEMBERS	MEETING MINUTES	NEW DRUGS	ALL RECOMMENDATIONS BLOCK VOTE	CLOSED SESSION PURSUANT TO SECTION 610.021 SUBSECTION (14), (5)	ADJOURN EXECUTIVE SESSION
Susan Abdel-Rahman, Pharm D	Y	Y	Y	Y	-
Charlene Heyde, RPh	-	-	-	-	-
Sandra Bollinger, Pharm D	S	S	M	M	-
Kenneth Haller, MD	-	-	-	-	-
Glenn Talboy, MD	Y	Y	Y	Y	-
Jennifer Passanise, FNP	M	Y	S	Y	-
Stacy Mangum, Pharm D	Y	M	Y	Y	-
Kirk Nelson, MD	-	-	-	-	-
Ginger Nicol, MD	Y	Y	Y	Y	-
Randy Beckner, Pharm D	Y	Y	Y	S	-

EXECUTIVE SESSION
July 19, 2017

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, Pharm D – Board Chair
Stacy Mangum, Pharm D
Sandra Bollinger, Pharm D
Jennifer Passanise, FNP
Randy Beckner, Pharm D
Ginger Nicol, MD
Glen Talboy, MD

MHD STAFF PRESENT

Stephen Calloway, RPh, Director of Pharmacy
Mark Roaseau, RPh, Clinical Pharmacist
Angela Wilson, Manager Band I
Lisa Smith, Program Development Specialist
Franki Moseley, Administrative Office Support Assistant

DUR BOARD MEMBERS ABSENT

Charlene Heyde, RPh
Kenneth Haller, MD
Kirk Nelson, MD

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Richard Pope, Pharm D, Magellan

Minutes Review	Minutes of the April Executive Session were approved as submitted.
Case Reviews	None
Adjourn	No Executive session.